Duo-5200 mg+125 mg

Duo-5 is a combination antibiotic used to treat bacterial infections caused by organisms that produce beta-lactamase enzymes, which would otherwise make the infection resistant to cefpodoxime alone. The clavulanic acid component blocks these enzymes, restoring the effectiveness of cefpodoxime against a broader range of bacteria.

Established/Guideline-supported uses

• Upper and lower respiratory tract infections, including acute bacterial sinusitis, pharyngitis/tonsillitis, and acute exacerbation of chronic bronchitis, when caused by beta-lactamase-producing pathogens.
• Community-acquired pneumonia due to susceptible, beta-lactamase-producing organisms.
• Acute otitis media in children caused by beta-lactamase-producing strains.
• Uncomplicated urinary tract infections caused by beta-lactamase-producing organisms.
• Skin and soft tissue infections (e.g. cellulitis, abscess, wound infection) caused by beta-lactamase-producing bacteria.
• Ear, nose and throat (ENT) infections such as recurrent or treatment-resistant sinusitis and otitis media.

Duo-5 should only be used for infections confirmed or strongly suspected to be caused by susceptible bacteria. It is not effective against viral infections such as the common cold or flu.

Cefpodoxime Proxetil + Clavulanic Acid is a fixed-dose combination containing two active ingredients:

• Cefpodoxime Proxetil - a third-generation oral cephalosporin antibiotic (prodrug that is converted to active cefpodoxime after absorption).
• Clavulanic Acid - a beta-lactamase inhibitor with negligible antibacterial activity of its own, included to protect cefpodoxime from breakdown by bacterial beta-lactamase enzymes.

Common strengths marketed include tablets (e.g. cefpodoxime 200 mg with clavulanic acid 125 mg) and oral suspension for pediatric use (e.g. cefpodoxime 50 mg with clavulanic acid per 5 mL after reconstitution). Exact strengths vary by manufacturer and market.

Duo-5 combines a third-generation cephalosporin antibiotic with a beta-lactamase inhibitor. Cefpodoxime alone is active against many gram-positive and gram-negative bacteria, but some strains produce beta-lactamase enzymes that destroy the drug before it can act. Clavulanic acid inhibits these enzymes, allowing cefpodoxime to remain active against a wider range of resistant organisms.

Duo-5 is available as film-coated tablets and as a powder for oral suspension that must be reconstituted with water before use. It is taken by mouth and is used only for bacterial infections diagnosed or strongly suspected by a physician.

Duo-5 belongs to the class of third-generation cephalosporin antibiotics combined with a beta-lactamase inhibitor, a combination class analogous to amoxicillin-clavulanate but built on a cephalosporin backbone. It is used for the treatment of susceptible bacterial infections.

Mechanism of action

Cefpodoxime, the active component of Cefpodoxime Proxetil + Clavulanic Acid, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), which interferes with the final transpeptidation step of peptidoglycan cross-linking. This leads to cell wall instability and bacterial cell death (bactericidal action).

Many bacteria produce beta-lactamase enzymes that hydrolyze the beta-lactam ring of cephalosporins, inactivating them before they can reach their target. Clavulanic acid is a suicide inhibitor of many beta-lactamase enzymes: it binds irreversibly to the enzyme, protecting cefpodoxime from degradation and extending its spectrum of activity to include many beta-lactamase-producing strains of Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis, and certain Enterobacteriaceae.

Pharmacokinetics

Cefpodoxime proxetil is an inactive prodrug that is hydrolyzed by intestinal esterases to active cefpodoxime during absorption. Absorption is enhanced by an acidic gastric environment and by food. Cefpodoxime is widely distributed in body tissues and fluids and is eliminated mainly unchanged by the kidneys, with a plasma half-life of approximately 2 to 3 hours in adults with normal renal function. Clavulanic acid is also well absorbed orally, metabolized in the liver, and excreted renally.

Duo-5 tablets should be swallowed whole with food; do not crush or chew unless a specific formulation permits it. The oral suspension must be reconstituted with the correct amount of water as directed on the label, shaken well before each use, and measured with an accurate oral syringe or measuring cup - not a household spoon. Try to take doses at evenly spaced intervals (e.g. every 12 hours) to maintain steady drug levels. If a dose is missed, take it as soon as remembered unless it is nearly time for the next dose; do not double the dose.

Duo-5 can interact with the following medicines; inform your physician about all medications you are taking:

• Antacids, H2-receptor blockers (e.g. ranitidine, famotidine), and proton pump inhibitors (e.g. omeprazole): These reduce stomach acidity, which is needed for optimal absorption of cefpodoxime, and can significantly lower blood levels of the drug and reduce its effectiveness. If concurrent use is unavoidable, doses should be separated as far apart as possible and the physician should be informed.
• Probenecid: Competes with cefpodoxime for renal tubular secretion, increasing and prolonging cefpodoxime blood levels; concurrent use may require dose adjustment.
• Hormonal (oral) contraceptives: Antibiotics may theoretically reduce the effectiveness of oral contraceptives by altering gut flora involved in enterohepatic recycling of estrogens. As a precaution, an additional (barrier) method of contraception is advised during treatment and for a short period afterward.
• Warfarin and other oral anticoagulants: Concurrent use may potentiate the anticoagulant effect (partly via alteration of gut flora that produce vitamin K), increasing bleeding risk. INR should be monitored more closely if these are used together.

Like all medicines, Duo-5 can cause side effects, though not everyone experiences them.

Common

• Diarrhea, loose stools, nausea, vomiting, abdominal pain or discomfort (the clavulanic acid component is associated with a higher rate of gastrointestinal upset than cefpodoxime alone).
• Skin rash.
• Headache.

Less common / Serious

• Hypersensitivity reactions, including urticaria (hives), itching, and, rarely, severe anaphylactic reactions.
• Clostridioides difficile-associated diarrhea (antibiotic-associated colitis), which can range from mild to life-threatening and may occur during or after treatment (class warning for cephalosporins).
• Liver enzyme elevations and, rarely, cholestatic jaundice or hepatic dysfunction, more often reported with clavulanic acid-containing combinations, sometimes with delayed onset after stopping the medicine.
• Vaginal candidiasis (yeast infection).
• Rarely, blood count changes (e.g. eosinophilia) or a positive direct Coombs test without hemolysis.

Seek urgent medical attention for signs of a severe allergic reaction (swelling of the face/throat, difficulty breathing, severe rash), watery or bloody diarrhea that does not improve, or yellowing of the skin/eyes.

Pregnancy: Cephalosporins as a class are generally considered to carry a comparatively lower risk profile among antibiotics in pregnancy, but adequate, well-controlled studies specifically on Duo-5 in pregnant women are limited. Duo-5 should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus, and only under a physician's direction.

Lactation: Cefpodoxime and clavulanic acid are excreted in small amounts into breast milk. Use during breastfeeding should be discussed with a physician, weighing the benefit of treatment against the possibility of effects on the nursing infant (e.g. diarrhea or thrush), and the infant should be monitored if the mother is treated with Duo-5.

• Use with caution in patients with a history of penicillin allergy because of possible cross-reactivity with cephalosporins; observe closely for allergic reactions after the first dose.
• Use cautiously in patients with significant renal impairment; dose interval adjustment may be needed (see Dosage and Administration).
• Prolonged use may result in overgrowth of non-susceptible organisms, including Clostridioides difficile; seek medical attention if severe or persistent diarrhea develops.
• Monitor liver function in patients with pre-existing liver disease or those on prolonged therapy, due to the association of the clavulanic acid component with hepatic effects.
• Antibiotic stewardship: Take exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice. Inappropriate use can lead to treatment failure and the development of antibiotic-resistant bacteria.
• Duo-5 does not treat viral infections (such as colds or flu) and should not be used for these.

Overdose with Duo-5 may cause pronounced gastrointestinal symptoms (nausea, vomiting, diarrhea, abdominal pain) and, in some cases, disturbances of fluid and electrolyte balance or neuromuscular excitability/seizures, particularly in patients with renal impairment. There is no specific antidote.

If an overdose is suspected, seek immediate medical attention or contact a poison control center / emergency services. Treatment is supportive; hemodialysis can help remove cefpodoxime from the body in severe cases of renal impairment. Do not attempt to manage a suspected overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Reconstituted oral suspension should be stored as directed on the label (typically in a refrigerator, not frozen) and any unused portion discarded after the labeled period, usually 14 days.

Pediatric use

Duo-5 oral suspension is used in children for approved indications (e.g. acute otitis media, pharyngitis, sinusitis, skin infections) caused by beta-lactamase-producing organisms, dosed by body weight according to the physician's prescription. Safety and efficacy in neonates and infants under a few months of age have not been well established; use in this group should be guided by a pediatrician.

Elderly

No specific dose adjustment is generally required in elderly patients with normal renal function, but since renal function often declines with age, kidney function should be assessed and the dose adjusted accordingly.

Renal impairment

Dose interval should be extended in patients with significant renal impairment (see Dosage and Administration).

Hepatic impairment

Use with caution; monitor liver function, especially with prolonged treatment.

The typical duration of Duo-5 treatment ranges from 5 to 14 days depending on the type and severity of infection (see the dosing table in Dosage and Administration). The full course prescribed by the physician should always be completed, even if symptoms resolve earlier, to ensure the infection is fully cleared and to reduce the risk of relapse and antibiotic resistance.

The oral suspension form of Duo-5 is supplied as a dry powder that must be reconstituted with a specified amount of clean drinking water before use, as directed on the product label. After adding water, shake the bottle vigorously until the powder is fully and evenly dispersed. Store the reconstituted suspension in a refrigerator (do not freeze) and shake well before each dose. Discard any unused suspension after the period stated on the label (commonly 14 days after reconstitution), and do not use it beyond that period even if it appears unchanged.

Third-generation cephalosporin antibiotic + beta-lactamase inhibitor combination

The cefpodoxime component of Cefpodoxime Proxetil + Clavulanic Acid binds to penicillin-binding proteins in the bacterial cell wall, blocking the final cross-linking step of peptidoglycan synthesis; this weakens the cell wall and causes bacterial cell lysis and death. The clavulanic acid component has minimal intrinsic antibacterial activity but irreversibly inhibits many bacterial beta-lactamase enzymes, preventing them from destroying cefpodoxime. Together, this combination restores and extends cefpodoxime's activity against beta-lactamase-producing bacterial strains that would otherwise be resistant.

Duo-5 oral suspension may be prescribed by a pediatrician for children with confirmed or strongly suspected bacterial infections caused by beta-lactamase-producing organisms, such as acute otitis media, streptococcal pharyngitis/tonsillitis, sinusitis, and certain skin/soft tissue infections. Dosing is calculated based on the child's body weight and the specific infection being treated.

Safety and efficacy have not been formally established in neonates and very young infants, and Duo-5 should only be used in this age group under close pediatric supervision. Parents/caregivers should complete the full prescribed course and should not adjust the dose or stop treatment early without consulting the physician.